News

This week, read articles from our recent issue on topics including invasive fungal disease in transplantation, lenacapavir's role in PrEP, antimicrobial treatment around non–carbapenemase-producing carbapenem-resistant enterobacterales, and more.

Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.

Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a recent MMWR.

We are launching our new monthly column looking at federal regulatory topics including recent decisions. In this column, we look at the FDA approvals of 2 antibiotics last month.

How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on the incidence trends among teens, and what severe disease complications look like for young children.

Non–carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) isolates are the most common mechanism of CRE in the United States, but the optimal antimicrobial treatment remains to be elucidated.

Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.

Invasive fungal diseases remain a major cause of morbidity and mortality in patients undergoing transplant, with shifting epidemiology, emerging resistance, and geographic variation underscoring the urgent need for improved surveillance, prevention strategies, and antifungal stewardship.

The COVID-19 pandemic intensified long-standing problems in scientific production and communication—driven by perverse academic incentives, peer review strain, media hype, and growing misuse of AI—highlighting the urgent need for stronger critical appraisal skills across research and medicine.

This week, listen in on commentary around the changes to the childhood vaccine schedule, read SIDP's column on the next-generation antifungals as well as combination therapeutics for Candida auris, and the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing breakpoint recommendations.

Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.

The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, discusses her approach to training for these care scenarios.

Findings from a recent study challenge the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.

A recent study examined how rurality and the availability of postdischarge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.

With rates of influenza vaccination in decline, two health systems evaluated interventions for prompting clinicians to order, and patients to obtain flu shots.

Former FDA Chief Scientist Jesse L. Goodman, MD, MPH, provides insights on the potential consequences of these new recommendations.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, talks about safely responding to deadly pathogens such as Ebola and Lassa fever, and where the US is in terms of thinking about preparedness on a national level.

New federal guidance recommends childhood vaccines for 11 diseases, downsizing immunization protection from the previous list of 18 diseases.

A delay in providing standard infant vaccinations is associated with children not receiving MMR (measles, mumps, rubella) vaccine by 2 years of age.

A series of politically driven actions in 2025—including defunding mRNA research, dismantling vaccine advisory bodies, and restricting CDC recommendations—has undermined US vaccine access and pandemic preparedness, but professional societies and some states are stepping in to preserve evidence-based public health.

This week, read about increasing influenza activity, an approach to de-escalating empiric broad spectrum antibiotics for clinically stable patients with community-onset sepsis, and more Emory Healthcare Media Day interviews around PPE and treating high-consequence infectious disease.

Jill Morgan, RN, BSN, talks about steps being taken to ensure everyone’s safety is front of mind.

CDC surveillance shows sharp week-over-week increases in influenza test positivity, outpatient illness, and hospital admissions, with A(H3N2) continuing to predominate nationwide.

The recent CDC ACIP meetings and subsequent actions show a path for which the current Health and Human Services department wants to roll back access to vaccines for this virus and other vaccines.

Jill Morgan, RN, BSN, reviews this significant part of clinical care and how personal protective equipment (PPE) is essential to protecting healthcare workers.

Emory's Gavin Harris, MD, discusses these elements, and how despite the fact they rarely occur, the need to do continuous training is essential for readiness.